Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model
Objectives. The aim of this prospective cohort, multicentre study was to assess the effect of coadministrating ezetimibe 10?mg/day with an ongoing statin on the estimated risk for Cardiovascular (CVD) mortality in patients with persistently elevated LDL-C after statin monotherapy. Methods. The Systematic Coronary Risk Evaluation (SCORE) function was used to estimate the 10-year risk for cardiovascular mortality at baseline and 6 weeks. Primary outcome measures were absolute and percent changes in estimated Coronary Heart Disease (CHD) Mortality Risk, and general CVD Mortality Risk (Total CVD Mortality Risk). Results. 825 patients were included in the analysis. Mean (SD) age was 62 (10.5) years and 62.3% were males. The mean (SD) estimated Total CVD Mortality Risk decreased from 0.068 (0.059) at baseline to 0.053 (0.046) at 6 weeks ( ; 95% CI:0.689–0.867), while the estimated CHD Mortality Risk decreased from 0.047 (0.040) at baseline to 0.034 (0.029) at 6 weeks ( ; 95% CI:0.624–0.826). Conclusions. Co-administration of ezetimibe with a statin is effective in significantly reducing the estimated risk for cardiovascular mortality as measured by the SCORE model. 1. Introduction Cardiovascular disease is the major cause of mortality in Canada, accounting for one-third of all deaths, with an incidence expected to increase within the next decade [1]. Increased serum cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is directly associated with an increased risk for cardiovascular disease (CVD) [2–5]. Initiation of lipid-lowering pharmacologic intervention for the management of hypercholesterolaemia is generally dependent on the individual patient’s estimated risk for cardiovascular events [3, 6, 7]. Ultimately, the aim of lipid-lowering treatment is to effectively reduce the individual patient’s risk for CVD, thus decreasing related mortality, morbidity and burden of illness. A cardiovascular risk prediction model was developed by the SCORE (Systemic COronary Risk Evaluation) project group in accordance to the recommendations from the Second Joint Task Force of European and other Societies on Coronary Prevention [7]. The SCORE model is based on pooled data from 12 European cohort studies, including data on over 205,000 individuals and representing 2.7 million person-years of followup. The model predicts the individual’s 10-year risk for fatal cardiovascular events on the basis of age, gender, smoking status, systolic blood pressure (SBP), and total cholesterol (TC). The total SCORE risk is further subdivided into the risk for fatal CHD and
M. Evans, A. Roberts, and A. Rees, “Pharmacological management of hyperlipidaemia,” British Journal of Diabetes and Vascular Disease, vol. 3, no. 3, pp. 204–210, 2003.
[3]
S. M. Grundy, J. I. Cleeman, C. N. Merz et al., “Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,” Journal of the American College of Cardiology, vol. 44, no. 3, pp. 720–732, 2004.
[4]
P. H. Jones, “Lower is better: LDL-C goal achievement and statin efficacy in coronary prevention,” Medscape Cardiology, vol. 8, no. 1, 2004.
[5]
C Baigent, A. Keech, P. M. Kearney, et al., “Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins,” The Lancet, vol. 366, pp. 1267–1278, 2005.
[6]
H.-W. Hense, H. Schulte, H. L?wel, G. Assmann, and U. Keil, “Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts,” European Heart Journal, vol. 24, no. 10, pp. 937–945, 2003.
[7]
R. M. Conroy, K. Py?r?l?, A. P. Fitzgerald et al., “Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project,” European Heart Journal, vol. 24, no. 11, pp. 987–1003, 2003.
[8]
J. Genest, J. Frohlich, G. Fodor, and R. McPherson, “Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update,” CMAJ, vol. 169, no. 9, pp. 921–924, 2003.
[9]
J. Genest, R. McPherson, J. Frohlich et al., “2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations,” Canadian Journal of Cardiology, vol. 25, no. 10, pp. 567–579, 2009.
[10]
C. Bourgault, J. Davignon, G. Fodor et al., “Statin therapy in Canadian patients with hypercholesterolemia: the Canadian lipid study—observational (CALIPSO),” Canadian Journal of Cardiology, vol. 21, no. 13, pp. 1187–1193, 2005.
[11]
K. A. Foley, R. J. Simpson Jr., J. R. Crouse III, T. W. Weiss, L. E. Markson, and C. M. Alexander, “Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events,” American Journal of Cardiology, vol. 92, no. 1, pp. 79–81, 2003.
[12]
T. A. Pearson, I. Laurora, H. Chu, and S. Kafonek, “The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals,” Archives of Internal Medicine, vol. 160, no. 4, pp. 459–467, 2000.
[13]
R. H. Knopp, H. Gitter, T. Truitt et al., “Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia,” European Heart Journal, vol. 24, no. 8, pp. 729–741, 2003.
[14]
S. E. Conard, H. E. Bays, L. A. Leiter et al., “Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease conflicts of interest,” American Journal of Cardiology, vol. 102, no. 11, pp. 1489–1494, 2008.
[15]
L. A. Leiter, H. Bays, S. Conard et al., “Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease,” American Journal of Cardiology, vol. 102, no. 11, pp. 1495–1501, 2008.
[16]
H. W. O. Roeters van Lennep, H. L. An, P. H. J. M. Dunselman, G. M. Dallinga-Thie, A. H. Zwinderman, and J. W. Jukema, “The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study,” Current Medical Research and Opinion, vol. 24, no. 3, pp. 685–694, 2008.
[17]
M. Farnier, M. Averna, L. Missault et al., “Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy—the IN-CROSS study,” International Journal of Clinical Practice, vol. 63, no. 4, pp. 547–559, 2009.
[18]
T. Feldman, M. Koren, W. Insull Jr. et al., “Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals,” American Journal of Cardiology, vol. 93, no. 12, pp. 1481–1486, 2004.
[19]
E. Stein, S. Stender, P. Mata et al., “Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin,” American Heart Journal, vol. 148, no. 3, pp. 447–455, 2004.
[20]
M. A. Ostad, S. Eggeling, P. Tschentscher, et al., “Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study,” Atherosclerosis, vol. 205, no. 1, pp. 227–232, 2009.
[21]
K. Hedenmalm, G. Alvan, P. ?hagen, and M.-L. Dahl, “Muscle toxicity with statinsy,” Pharmacoepidemiology and Drug Safety, vol. 19, no. 3, pp. 223–231, 2010.
[22]
M. H. Davidson and J. G. Robinson, “Safety of aggressive lipid management,” Journal of the American College of Cardiology, vol. 49, no. 17, pp. 1753–1762, 2007.
[23]
S. Bissonnette, R. Habib, F. Sampalis, S. Boukas, and J. S. Sampalis, “Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: a Canadian, multicentre, prospective study—the Ezetrol add-on study,” Canadian Journal of Cardiology, vol. 22, no. 12, pp. 1035–1044, 2006.
[24]
T. Thom, N. Haase, W. Rosamond et al., “Heart disease and stroke statistics—2006 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Circulation, vol. 113, no. 6, pp. e85–e151, 2006.
[25]
D. P. Mikhailidis, G. C. Sibbring, C. M. Ballantyne, G. M. Davies, and A. L. Catapano, “Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy,” Current Medical Research and Opinion, vol. 23, no. 8, pp. 2009–2026, 2007.
[26]
D. B. Araujo, M. C. Bertolami, W. P. Ferreira et al., “Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration,” Journal of Cardiovascular Pharmacology, vol. 55, no. 1, pp. 1–5, 2010.
[27]
M. Yamaoka-Tojo, T. Tojo, R. Kosugi, et al., “Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia,” Lipids in Health and Disease, vol. 8, article 41, 2009.
[28]
T. A. Pearson, C. M. Ballantyne, E. Veltri et al., “Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy,” American Journal of Cardiology, vol. 103, no. 3, pp. 369–374, 2009.
[29]
P. J. Devine, M. A. Turco, and A. J. Taylor, “Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in atherosclerosis (HALTS),” Cardiovascular Drugs and Therapy, vol. 21, no. 3, pp. 221–225, 2007.
[30]
C. P. Cannon, R. P. Giugliano, M. A. Blazing et al., “Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes,” American Heart Journal, vol. 156, no. 5, pp. 826–832, 2008.
[31]
C. Cooke, L. Nissen, I. Sketris, and S. E. Tett, “Quantifying the use of the statin antilipemic drugs: comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia,” Clinical Therapeutics, vol. 27, no. 4, pp. 497–508, 2005.